A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines
Latest Information Update: 25 Aug 2022
Price :
$35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Acronyms DREAM
- Sponsors Galderma; Q-Med
- 31 May 2022 According to a Galderma media release, Pooled data from NCT03736928, Phase 2; NCT03960957, Phase 3; NCT03687736, Phase 4 will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
- 25 Apr 2021 Results of post-hoc analysis, evaluating subject satisfaction following on-label injections of 50U of AbobotulinumtoxinA in the glabellar lines at baseline and re-treatment at 6 months, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 09 Oct 2020 According to a Galderma media release, results from this study will be presented at the virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting.